Ontology highlight
ABSTRACT:
SUBMITTER: Dumet C
PROVIDER: S-EPMC6816381 | biostudies-literature | 2019 Nov-Dec
REPOSITORIES: biostudies-literature
Dumet Christophe C Pottier Jérémy J Gouilleux-Gruart Valérie V Watier Hervé H
mAbs 20190926 8
Despite being the least abundant immunoglobulin G in human plasma, IgG4 are used therapeutically when weak effector functions are needed. The increase in engineered IgG4-based antibodies on the market led us to study the patent landscape of IgG4 Fc engineering, <i>i.e</i>., patents claiming modifications in the heavy chain. Thirty-seven relevant patent families were identified, comprising hundreds of IgG4 Fc variants focusing on removal of residual effector functions (since IgG4s bind to FcγRI a ...[more]